Spectrum Pharmaceuticals (SPPI) Getting Somewhat Favorable Press Coverage, Study Shows
Press coverage about Spectrum Pharmaceuticals (NASDAQ:SPPI) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.967795629017 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Facts, figures and statistics of: Spectrum Pharmaceuticals, Inc., (NASDAQ: SPPI), MasTec, Inc., (NYSE: MTZ … – Stocks In The News (press release) (tradingnewsnow.com)
- Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors (americanbankingnews.com)
- Why Spectrum Pharmaceuticals Stock Soared in October (fool.com)
- Technical Review of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) – The Oracle Examiner (oracleexaminer.com)
- Analyst’s Review to Watch: Spectrum Pharma Inc (SPPI) – ExpertGazette (expertgazette.com)
Shares of Spectrum Pharmaceuticals (SPPI) traded down $0.22 on Friday, hitting $18.33. The stock had a trading volume of 895,500 shares, compared to its average volume of 1,080,225. Spectrum Pharmaceuticals has a 12-month low of $3.85 and a 12-month high of $21.95. The company has a current ratio of 5.04, a quick ratio of 4.89 and a debt-to-equity ratio of 0.33.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.06). The company had revenue of $36.40 million for the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The company’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.07) earnings per share. sell-side analysts predict that Spectrum Pharmaceuticals will post -1.03 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on SPPI shares. Guggenheim started coverage on Spectrum Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $32.00 price target on the stock. Jefferies Group LLC upped their price target on Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a research report on Friday, October 20th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target (up from $20.00) on shares of Spectrum Pharmaceuticals in a research report on Wednesday, October 18th. Zacks Investment Research cut Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $21.40.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.